Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1613-1621

  Shi, Nian Qiu ^a   Gao, Wei ^a   Xiang, Bai ^a   Qi, Xian Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Activable cell penetrating peptide; Antiproliferative; Cellular uptake; Enzymatic cleavage; Matrix metalloproteinase; Proteinase sensitive substrate; Tumor extracellular environment

Indexed keywords

ACTIVABLE CELL PENETRATING PEPTIDE CONJUGATE; ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; UNCLASSIFIED DRUG; ACID PHOSPHATASE PROSTATE ISOENZYME; DOXORUBICIN; MMP2 PROTEIN, HUMAN; PROTEIN TYROSINE PHOSPHATASE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PROTEIN CLEAVAGE; ACTIVE TRANSPORT; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; FEMALE; FIBROSARCOMA; METABOLISM; NANOMEDICINE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FIBROSARCOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NANOMEDICINE; PROTEIN TYROSINE PHOSPHATASES;

EID: 84866528463     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30104     Document Type: Article

References (38)

1. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91(2):664-668.
2. Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004;11(8):1165-1175.
3. Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000;6(11):1253-1257.
4. Santra S, Yang H, Stanley JT, et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem Commun (Camb). 2005;7(25):3144-3146.
5. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18(4):410-414.
6. Mazel M, Clair P, Rousselle C, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs. 2001; 12(2):107-116.
7. Liang JF, Yang VC. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett. 2005;15(22):5071-5075.
8. Aroui S, Brahim S, De Waard M, Bréard J, Kenani A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009;285(1):28-38.
9. Aroui S, Brahim S, Hamelin J, De Waard M, Bréard J, Kenani A. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAILinduced apoptosis. Apoptosis. 2009;14(11):1352-1365.
10. Lindgren M, Rosenthal-Aizman K, Saar K, et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2006;71(4):416-425.
11. Aroui S, Brahim S, Waard MD, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun. 2010;391(1):419-425.
12. Ma DX, Shi NQ, Qi XR. Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells. Int J Pharm. 2011;419(1-2):200-208.
13. Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786(2): 126-138.
14. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61(11):953-964.
15. Law B, Tung CH. Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. Bioconjug Chem. 2009;20(9):1683-1695.
16. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101(51):17867-17872.
17. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb). 2009;1(5-6): 371-381.
18. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb). 2009;1(5-6):382-393.
19. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A. 2010;107(9): 4311-4316.
20. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A. 2010;107(9):4317-4322.
21. Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 1998;16(8):483-496.
22. Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008;82(9-10): 467-476.
23. Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 2005;4(5):751-760.
24. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31(17):4748-4756.
25. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5):290-308.
26. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A. 2000;97(24):13003-13008.
27. Kline T, Torgov MY, Mendelsohn BA, Cerveny CG, Senter PD. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and-9. Mol Pharm. 2004;1(1):9-22.
28. Smith R, Sewell SL, Giorgio TD. Proximity-activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavage. Int J Nanomedicine. 2008;3(1):95-103.
29. Wang PC, Qi XR. The design and enzymatic hydrolysis of activatable cell-penetrating peptide. Yao Xue Xue Bao. 2010;45(8):1048-1051.
30. Sun Y, Yan X, Yuan T, et al. Disassemblable micelles based on reduction-degradable amphiphilic graft copolymers for intracellular delivery of doxorubicin. Biomaterials. 2010;31(27):7124-7131.
31. Li YL, Zhu L, Liu Z, et al. Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells. Angew Chem Int Ed Engl. 2009;48(52):9914-9918.
32. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEGmatrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006;111(3):333-342.
33. 2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem. 2004;328(2): 166-173.
34. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cellselective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 2000;60(21):6061-6067.
35. Bullok KE, Dyszlewski M, Prior JL, Pica CM, Sharma V, Piwnica-Worms D. Characterization of novel histidine-tagged Tat-peptide complexes duallabeled with (99 m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug Chem. 2002;13(6):1226-1237.
36. Robbins PB, Oliver SF, Sheu SM, Goodnough JB, Wender P, Khavari PA. Peptide delivery to tissues via reversibly linked protein transduction sequences. Biotechniques. 2002;33(1):190-192, 194.
37. Torchilin VP, Levchenko TS. TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci. 2003;4(2):133-140.
38. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci U S A. 2008;105(34):12128-12133.